Dr. Igor Puzanov, MD

Dr. Puzanov practices at Roswell Park Cancer Institute in Los Angeles, California.

Dr. Puzanov's NPI, 1700892502, was assigned on August 1, 2006. Dr. Puzanov holds New York license 286657.

Dr. Puzanov's primary practice is Roswell Park Cancer Institute, at 344 S Hauser Blvd, Los Angeles, CA 90036 in Los Angeles County. The practice phone is (716) 845-2300.

Dr. Puzanov's primary practice is Roswell Park Cancer Institute in Los Angeles, California. Dr. Puzanov is also affiliated with Roswell Park Comprehensive Cancer Center. The medical group on file is Roswell Park Comprehensive Cancer Center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Puzanov practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Puzanov's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Puzanov's licenses on file in 2 states: New York and Tennessee.

CMS data shows 58 Medicare services from Dr. Puzanov across 2 procedure codes in 2024, all of them office visits, for 36 Medicare patients. Medicare paid $5,448 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 36 Medicare patients who saw Dr. Puzanov in 2024. The largest group is 65 to 74, with 17 patients. 75% of them have high blood pressure, and 67% have high cholesterol. Their average risk score is 2.74, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Puzanov's median patient age at 73, with 39% women.

In 2024, Dr. Puzanov wrote 26 Medicare Part D claims. 100% of them were for generic drugs. CMS names the drug for 13 of them, across 1 drug with 11 or more claims each, at $137 in total drug cost. In 2019, CMS named 15 claims across 1 drug.

Dr. Puzanov accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 183 papers to Dr. Puzanov, published from 2011 to 2025. 2016 was the busiest year, with 18. The most frequent topics are Melanoma, Immunotherapy and Skin Neoplasms. Dr. Puzanov has published most often in J Transl Med. Dr. Puzanov's most frequent co-authors are Jeffrey A. Sosman, MD, Marc Stuart Ernstoff, MD and Omid Hamid, MD.

Dmand AI links Dr. Puzanov to 11 clinical trials, 7 of them phase 2 studies. 7 are still active or recruiting. Conditions studied include Melanoma, Nevi and Melanomas and Brain Neoplasms. National Cancer Institute (NCI) sponsors the most, 5. Open Payments lists research payments to Dr. Puzanov that name 1 trial.

CMS Open Payments shows 177 general payments to Dr. Puzanov from 15 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 47% of the total. Bristol-Myers Squibb Company paid the most, $56,564. It also lists 16 research payments totaling $18,206 from 2016 to 2020, naming 1 clinical trial.